Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients.

about

Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients.

Item

http://www.wikidata.org/entity/Q55417294

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Sirukumab in rheumatoid arthri ...... cy study in Japanese patients.

@en

Sirukumab in rheumatoid arthri ...... cy study in Japanese patients.

@nl

type

Item

label

Sirukumab in rheumatoid arthri ...... cy study in Japanese patients.

@en

Sirukumab in rheumatoid arthri ...... cy study in Japanese patients.

@nl

prefLabel

Sirukumab in rheumatoid arthri ...... cy study in Japanese patients.

@en

Sirukumab in rheumatoid arthri ...... cy study in Japanese patients.

@nl

P1476

Sirukumab in rheumatoid arthri ...... cy study in Japanese patients.

@en

P2093

Benjamin Hsu

http://www.w3.org/2001/XMLSchema#string

Hisashi Yamanaka

http://www.w3.org/2001/XMLSchema#string

Masayoshi Harigai

http://www.w3.org/2001/XMLSchema#string

Ryo Tamamura

http://www.w3.org/2001/XMLSchema#string

Toshikazu Nakano

http://www.w3.org/2001/XMLSchema#string

Yoshifumi Ukyo

http://www.w3.org/2001/XMLSchema#string

Yoshiya Tanaka

http://www.w3.org/2001/XMLSchema#string

Yuichi Kato

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of risk factors for elevated transaminases in methotrexate users through an electronic health record.

Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.

Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study.

Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy.

Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis.

Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.

Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors

Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study.

Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.

P2888

s13075-018-1536-9

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13075-018-1536-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Tsutomu Takeuchi

P577

2018-03-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1101373669

http://www.w3.org/2001/XMLSchema#string

P698

29514712

http://www.w3.org/2001/XMLSchema#string

P932

5842593

http://www.w3.org/2001/XMLSchema#string